Cytotherapy

SCI SCIE

国际简称：CYTOTHERAPY 参考译名：细胞疗法

主要研究方向：医学-生物工程与应用微生物非预警期刊审稿周期：偏慢,4-8周

《细胞疗法》(Cytotherapy)是一本由Elsevier Inc.出版的以医学-生物工程与应用微生物为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q1 JCR分区
144 年发文量
4.5 IF影响因子
未开放 是否OA
76 H-index
1999 创刊年份
Bimonthly 出版周期
English 出版语言

The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.

[ 查看全部 ]

投稿咨询加急咨询

Cytotherapy期刊信息

ISSN：1465-3249
出版语言：English
是否OA：未开放
E-ISSN：1477-2566
出版地区：NORWAY
是否预警：否
出版商：Elsevier Inc.
出版周期：Bimonthly
创刊时间：1999
开源占比：0.2313
Gold OA文章占比：33.33%
OA被引用占比：0.1612...
出版国人文章占比：0.04
出版撤稿占比：0
研究类文章占比：92.36%

Cytotherapy CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

6.4

1.249

0.849

学科类别	分区	排名	百分位
大类：Medicine 小类：Transplantation	Q1	10 / 55	82%
大类：Medicine 小类：Oncology	Q1	93 / 428	78%
大类：Medicine 小类：Genetics (clinical)	Q2	27 / 100	73%
大类：Medicine 小类：Immunology and Allergy	Q2	78 / 234	66%
大类：Medicine 小类：Immunology	Q2	85 / 243	65%
大类：Medicine 小类：Cancer Research	Q2	85 / 233	63%
大类：Medicine 小类：Cell Biology	Q2	123 / 289	57%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Cytotherapy中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	CELL & TISSUE ENGINEERING 细胞与组织工程 BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 CELL BIOLOGY 细胞生物学 HEMATOLOGY 血液学 MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验	3区 3区 3区 3区 3区

Cytotherapy JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY	SCIE	Q2	57 / 180	68.6
学科：CELL & TISSUE ENGINEERING	SCIE	Q2	14 / 32	57.8
学科：CELL BIOLOGY	SCIE	Q2	91 / 207	56.3
学科：HEMATOLOGY	SCIE	Q1	22 / 103	79.1
学科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q2	59 / 191	69.4
学科：BIOTECHNOLOGY & APPLIED MICROBIOLOGY	SCIE	Q2	63 / 180	65.28
学科：CELL & TISSUE ENGINEERING	SCIE	Q2	11 / 32	67.19
学科：CELL BIOLOGY	SCIE	Q2	78 / 207	62.56
学科：HEMATOLOGY	SCIE	Q1	25 / 103	76.21
学科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q2	65 / 191	66.23

Cytotherapy历年数据统计

影响因子

中科院分区

Cytotherapy中国学者发文选摘

1、Donor-and patient-derived interleukin 6 knockdown CD19-targeted chimeric antigen receptor T cells exhibit similar efficacy and safety in treating relapsed Bcell acute lymphoblastic leukemia patients after allogeneic hematopoietic stem cell transplantatio
Author: Sun, Ting; Ma, Jin-Feng; Jia, Xu; Xu, Shun-Zhe; Liu, Shen-Hao; Lyu, Xiao-Yu; Huang, Si-Man; Wu, Yan-Jun; Yao, Zhen; Qian, Chong-Sheng; Li, Zheng; Yu, Lei; Dai, Hai-Ping; Gong, Wen-Jie; Xue, Sheng-Li

Journal: CYTOTHERAPY. 2026; Vol. 28, Issue 6, pp. -. DOI: 10.1016/j.jcyt.2026.102118
2、Futuristic global cell and gene therapy regulations based on a review of today's leading framework
Author: Hashmi, Shahrukh K.; Jamil, M. Abdullah; de la Fuente, Josu; Mahlangu, Johnny; Ozelo, Margareth C.; Walters, Mark C.; Almannaei, Asma; Srivastava, Alok; Alzahrani, Hazza; Lu, Peihua; Kenet, Gili; Nomura, Kaori; Leboulch, Philippe

Journal: CYTOTHERAPY. 2026; Vol. 28, Issue 6, pp. -. DOI: 10.1016/j.jcyt.2026.102064
3、Etoposide plus cytarabine plus granulocyte colony-stimulating factor mitigates daratumumab-associated impairment on stem cell mobilization in newly diagnosed multiple myelom
Author: Zhu, Zhijuan; Li, Xiaofan; Chen, Xianling; Yuan, Xiaohong; Lin, Ting; Li, Nainong

Journal: CYTOTHERAPY. 2026; Vol. 28, Issue 5, pp. -. DOI: 10.1016/j.jcyt.2026.102075
4、CD19 chimeric antigen receptor T-cell therapy for the treatment of a patient with refractory Burkitt lymphoma after kidney transplan
Author: Zhang, Peiling; Xu, Qian; Zhang, Zheng; Zhao, Lei; Huang, Meijuan; Cai, Haodong; Zhu, Lan; Zheng, Miao

Journal: CYTOTHERAPY. 2026; Vol. 28, Issue 5, pp. -. DOI: 10.1016/j.jcyt.2026.102055
5、Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantatio
Author: Fu, Shan; Yu, Yinghui; Zhang, Mingming; Feng, Jingjing; Wang, Wenxin; Tu, Sanfang; Zhang, Qing; Zhao, Mingfeng; Huang, He; Hu, Yongxian; Wei, Guoqing

Journal: CYTOTHERAPY. 2026; Vol. 28, Issue 5, pp. -. DOI: 10.1016/j.jcyt.2026.102074
6、Clinical analysis of fecal microbiota transplantation for refractory acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a five-year retrospective stud
Author: Li, Minghui; Yuan, Fangfang; Li, Gangping; Fu, Yuewen; Wei, Xudong

Journal: CYTOTHERAPY. 2026; Vol. 28, Issue 4, pp. -. DOI: 10.1016/j.jcyt.2025.102043
7、Fate and function of exogenously administered mesenchymal stromal cells: current insights and future direction
Author: Sholcoohmand, Ali; Patel, Nilcita; Braid, Lorena; Dominici, Massimo; Heng, Tracy S. P.; Ankrum, James A.; Barua, Jayita; Caicedo, Andres; Creane, Michael; Davies, Lindsay; dos Santos, Claudia C.; Enes, Sara Rolandsson; English, Karen; Farge, Dominique; Fernandez-Garcia, Maria; Galipeau, Jacques; Kadri, Nadir; Khoury, Maroun; Kilfeather, Stephen; Krampera, Mauro; Krasnodembskaya, Anna; Lalu, Manoj; Le Blanc, Katarina; Moll, Guido; Nolta, Jan; O'Kane, Cecilia; Rocco, Patricia R. M.; Shi, Yufang; Weiss, Daniel J.; Viswanathan, Sowmya

Journal: CYTOTHERAPY. 2026; Vol. 28, Issue 2, pp. -. DOI: 10.1016/j.jcyt.2025.102007
8、Charge-reversed small extracellular vesicles from human adipose-derived mesenchymal stromal cells attenuate renal fibrosis postacute kidney injury by inhibiting epithelial-mesenchymal transition progression in SD rat mode
Author: Ping, Wenwen; Xu, Xiaoyan; Jiang, Yan; Yang, Rong; Xu, Luwei

Journal: CYTOTHERAPY. 2025; Vol. 27, Issue 6, pp. 753-765. DOI: 10.1016/j.jcyt.2025.02.004